Antiphospholipid syndrome and the brain in pediatric and adult patients

Lupus

Volumn 19, Issue 4, 2010, Pages 406-411

  Muscal, E ^a   Brey, R L ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

2 glycoprotein I; Anticardiolipin antibody; Antiphospholipid syndrome; Cerebrovascular disease; Lupus anticoagulant; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; PHOSPHOLIPID ANTIBODY; PLACEBO; WARFARIN;

ADULT; ADULT DISEASE; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLEEDING; BRAIN DAMAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHILDHOOD DISEASE; CHOREA; CLINICAL TRIAL; COGNITIVE DEFECT; DOSE RESPONSE; EPILEPSY; EVIDENCE BASED PRACTICE; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MIGRAINE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT PLANNING; VEIN THROMBOSIS;

ADULT; AGE FACTORS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BRAIN; CHILD; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE; THROMBOSIS;

EID: 77951233074     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309360808     Document Type: Review

References (30)

1. Trysberg E., Nylen K., Rosengren LE, et al. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003 ; 48: 2881-2887. (Pubitemid 37280617)
2. Chapman J., Cohen-Armon M., Shoenfeld Y., et al. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999 ; 8: 127-133. (Pubitemid 29103599)
3. Cikes N., Bosnic D., Sentic M. Non-MS autoimmune demyelination. Clin Neurol Neurosurg 2008 ; 110: 905-912.
4. Horstman LL, Jy W., Bidot CJ, et al. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation 2009 ; 6: 3.
5. Janardhan V., Wolf PA, Kase CS, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 2004 ; 35: 736-741. (Pubitemid 38280851)
6. Urbanus RT, Siegerink B., Roest M., et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009 ; 8: 998-1005.
7. Sanna G., Bertolaccini ML, Cuadrado MJ, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003 ; 42: 200-213. (Pubitemid 36305604)
8. Cervera R., Boffa MC, Khamashta MA, et al. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009 ; 18: 889-893.
9. Mejia-Romero R., Garcia-Carrasco M., Galarza-Maldonado C., et al. Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients. Clin Rheumatol 2008 ; 27: 891-897.
10. Cervera R., Khamashta MA, Font J., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003 ; 82: 299-308. (Pubitemid 37229465)
11. Bucciarelli S., Espinosa G., Cervera R. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus 2009 ; 18: 905-912.
12. Toloza SM, Uribe AG, McGwin G. Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004 ; 50: 3947-3957. (Pubitemid 39643943)
13. Roldan CA, Gelgand EA, Qualls CR, et al. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol 2005 ; 95: 1441-1447. (Pubitemid 40824764)
14. Rajamani K., Chaturvedi S., Jin Z., et al. Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study. Stroke 2009 ; 40: 2337-2342.
15. Hunt BJ Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2008 ; 34: 274-281.
16. Avcin T., Cimaz R., Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008 ; 122: e1100 - e1107.
17. Angelini L., Ravelli A., Caporali R., et al. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics 1994 ; 94: 500-503. (Pubitemid 24295030)
18. Avcin T., Benseler SM, Tyrrell PN, et al. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 2008 ; 59: 206-213. (Pubitemid 351272956)
19. von Scheven E., Glidden DV, Elder ME Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2002 ; 47: 414-420. (Pubitemid 34856131)
20. Harel L., Sandborg C., Lee T., et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006 ; 33: 1873-1877. (Pubitemid 44373226)
21. Menon S., Jameson-Shortall E., Newman SP, et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999 ; 42: 735-741. (Pubitemid 29171994)
22. Hanly JG, Hong C., Smith S., et al. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999 ; 42: 728-734. (Pubitemid 29171993)
23. Erkan D., Barbhaiya M., George D., et al. Moderate versus high-titer persistently anticardiolipin antibody positive patients: Are they clinically different and does high-titer anti-B2-glycoprotein-I antibody positivity offer additional predictive information? Lupus, online 24 November 2009.
24. Tomietto P., Annese V., DAgostini S., et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 2007 ; 57: 1461-1472. (Pubitemid 350308845)
25. Stosic M., Ambrus J., Garg N., et al. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol 2009 ; epub ahead of print.
26. Oliveira de Andrade DC, Borba EF, Bonfa E., et al. Quantifying subclinical central nervous lesions in primary antiphospholipid syndrome: the role of magnetization transfer imaging. J Magn Reson Imaging 2008 ; 27: 483-488. (Pubitemid 351354731)
27. Crowther MA, Ginsberg JS, Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003 ; 349: 1133-1138. (Pubitemid 37122325)
28. Arandomizedclinicaltrial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005 ; 3: 848-853.
29. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004 ; 291: 576-584. (Pubitemid 38500311)
30. Erkan D., Harrison MJ, Levy R., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007 ; 56: 2382-2391. (Pubitemid 47173586)